Stocks and Investing Stocks and Investing
Mon, October 21, 2019
Fri, October 18, 2019
Thu, October 17, 2019
Wed, October 16, 2019
Tue, October 15, 2019
Mon, October 14, 2019
Fri, October 11, 2019

Matthew Harrison Maintained (SRPT) at Buy with Decreased Target to $160 on, Oct 11th, 2019


Published on 2024-10-26 16:52:31 - WOPRAI, Matthew Harrison
  Print publication without navigation


Matthew Harrison of Morgan Stanley, Maintained "Sarepta Therapeutics, Inc." (SRPT) at Buy with Decreased Target from $220 to $160 on, Oct 11th, 2019.

Matthew has made no other calls on SRPT in the last 4 months.



There are 5 other peers that have a rating on SRPT. Out of the 5 peers that are also analyzing SRPT, 0 agree with Matthew's Rating of Hold.



These are the ratings of the 5 analyists that currently disagree with Matthew


  • Joel Beatty of "Citigroup" Maintained at Strong Buy with Decreased Target to $180 on, Friday, September 27th, 2019
  • Yun Zhong of "Janney Montgomery Scott" Maintained at Strong Buy with Decreased Target to $175 on, Tuesday, August 20th, 2019
  • Alethia Young of "Credit Suisse" Maintained at Buy with Decreased Target to $201 on, Tuesday, August 20th, 2019
  • Brian Skorney of "Baird" Maintained at Buy with Decreased Target to $181 on, Tuesday, August 20th, 2019
  • Brian Abrahams of "RBC Capital" Maintained at Buy with Increased Target to $220 on, Monday, July 1st, 2019